Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
1 finding from 1 review
All‐cause mortality · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Blood ammonia concentrations (units unspecified) · adults with cirrhosis and hepatic encephalopathy
3 findings from 1 review
no estimate extracted
1 study · 35 participants
Very low
no estimate extracted
1 study · 16 participants
Very low
no estimate extracted
1 study · 231 participants
Very low
Blood ammonia concentrations (µmol/L*week) · adults with cirrhosis and hepatic encephalopathy
2 findings from 1 review
Hepatic encephalopathy · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Health‐related quality of life · adults with cirrhosis and hepatic encephalopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Plasma ammonia concentration (µmol/L) · adults with cirrhosis and hepatic encephalopathy
1 finding from 1 review
Awareness of prolapse · women with anterior compartment pelvic organ prolapse
It is very uncertain whether anterior prolapse repair: native tissue changes awareness of prolapse (2 years) compared with absorbable mesh (very low certainty).
1 finding from 1 review
Repeat surgery for prolapse (stage 2 or greater) at 2 years · women with anterior compartment pelvic organ prolapse
It is very uncertain whether anterior prolapse repair: native tissue changes repeat surgery for prolapse (stage 2 or greater) at 2 years compared with absorbable mesh (very low certainty).
1 finding from 1 review
Recurrent anterior compartment prolapse (3 months to 2 years) · women with anterior compartment pelvic organ prolapse
Anterior prolapse repair: native tissue probably leads to higher recurrent anterior compartment prolapse (3 months to 2 years) compared with absorbable mesh (moderate certainty).
1 finding from 1 review
De novo dyspareunia · women with anterior compartment pelvic organ prolapse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bladder function ‐ Stress incontinence · women with anterior compartment pelvic organ prolapse
It is very uncertain whether anterior prolapse repair: native tissue changes stress urinary incontinence (2 years) compared with absorbable mesh (very low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes mortality compared with lactitol (very low certainty).
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes hepatic encephalopathy compared with lactitol (very low certainty).
1 finding from 1 review
Serious adverse events · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes serious adverse events compared with lactitol (very low certainty).
1 finding from 1 review
Secondary outcome: quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found